The cost of inefficiencies in clinical trials
Clinical trials are expensive, time-sensitive, and closely monitored, with sponsors and contract research organisations (CROs) under pressure to run studies …
Post
-
-
How Saudi Arabia is developing as a Middle East hub for clinical trials
Saudi Arabia is primed to emerge as the Middle East’s key hub for clinical trials, driven by both sustained state …
-
Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation
Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and bupropion HCl) to …
-
Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening
Buoyed by yet another strong quarter fuelled by obesity drug demand, Eli Lilly has raised its sales expectations for the …
-
BMS brings the buzz around late-stage readouts amid a so-so Q1
The prospect of upcoming pivotal readouts from Bristol Myers Squibb (BMS) has brought a buzz amongst investors, as the company …
-
LEO Pharma to acquire gene therapy company Replay
LEO Pharma has signed a definitive agreement for the acquisition of Replay, a gene therapy company that develops treatments for …
-
Thinning revenues: inside the $14bn Eliquis patent cliff
Eliquis (apixaban) is one of the most commercially consequential loss-of-exclusivity (LOE) events in recent pharmaceutical history, with patent expiries expected …
-
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
Chiesi has conducted the largest acquisition in its 90-year history, agreeing to buy KalVista Pharmaceuticals in a deal worth around …
-
Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy
Teva Pharmaceuticals will acquire neuroscience specialist, Emalex – a move which Teva executive, Evan Lippman, says effectively complements the company’s …
-
EU’s Joint Clinical Assessment system still finding its footing
In April, Ipsen’s Ojemda (tovorafenib) secured European Commission (EC) approval for the treatment of relapsed or refractory paediatric low-grade glioma. …
-
How eSource adoption is saving time and costs in clinical research
Clinical trial sites and sponsors are turning to eSource to ease pressures over costs and unlock efficiencies, with a recent …
-
Ray Therapeutics receives EMA PRIME status for gene therapy
Ray Therapeutics has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) for its RTx-015 gene therapy to …
-
Regeneron Q1 2026 net income falls 10% to $727m
Regeneron Pharmaceuticals has reported GAAP [Generally Accepted Accounting Principles] net income of $727m for the first quarter of 2026 (Q1 2026), …
-
Pfizer protects $6.4bn heart disease blockbuster from generics, for now
Pfizer has successfully warded off three drug manufacturers from placing generics referencing Vyndamax (tafamidis) on the US market, though the …
-
Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact
Eli Lilly is locking down on its rapid expansion strategy with a second deal this week – joining forces with …
